<DOC>
	<DOCNO>NCT00452907</DOCNO>
	<brief_summary>Test hypothesis repeat administration Artesunate/Amiodaquine , Artesunate/Sulfadoxine-Pyrimethamine Arthemeter-Lufemantrine treatment consecutive episode uncomplicated malaria reduces incidence uncomplicated falciparum malaria malaria attributable anemia</brief_summary>
	<brief_title>ACT MALI : Treatment Malaria Based Combination Therapies</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Body weight &gt; 5kg Residence investigator site area duration trial Axillary temperature ≥ 37,5°C Day 0 Confirmed Plasmodium falciparum infection , parasitemia range 2000 200000 asexual parasite /µl blood Danger sign sign severe malaria Other severe illness Allergy one drug Pregnant woman The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>